Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1535 - EGFR mutation is not a prognostic factor in completely resected lymph node–negative pulmonary adenocarcinoma (LNNPA)


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Nussara Leeladejkul


Annals of Oncology (2019) 30 (suppl_5): v585-v590. 10.1093/annonc/mdz258


N. Leeladejkul1, P. Chantranuwat2, P. Sitthideatphaiboon1, C. Teerapakpinyo3, S. Shuangshoti2, V. Benjacholamas4, N. Pornpattanarak4, C. Vinayanuwattikun1, V. Sriuranpong1

Author affiliations

  • 1 Medical Oncology Unit, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH
  • 2 Pathology, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH
  • 3 Chula Genepro Center,research Affairs, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH
  • 4 Surgery, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1535


EGFR mutation is the major driver mutation in East Asian lung cancer. By and large, this group of lung cancer patients has a better prognosis in advanced stage pulmonary adenocarcinoma. However, the prognostic role of these sensitizing EGFR mutations in early stage is uncertain. We aimed to investigate the prognostic value of EGFR mutation and other factors for tumor recurrence in completely resected LNNPA.


We recruited 220 patients with LNNPA who were diagnosed and treated at the King Chulalongkorn Memorial Hospital from January 1, 2009 to December 31, 2016. Recurrence included pathological diagnosis, imaging confirmations, or death. Recurrence-free survival was analyzed by univariable and multivariable Cox regression analyses.


Median follow up time was 4 (2.7-5.6) years. There were more female (62%), never smokers (68%), stage I (86%) and EGFR mutations (54%). The most common EGFR mutations were exon 19 deletion (51%) and L858R (43%). Most patients did not receive adjuvant treatment (85.6%). There were 60 out of 220 (27.3%) patients had recurrent disease. The median time to recurrence was 2.3 years. The rate of loco-regional, distant and both types of recurrence were 27%, 68% and 5% respectively. Univariate analysis revealed smoking ≥ 10 pack-year, performance status ≥ 2, tumor size ≥ 4 cm, histologic grade ≥ 2, lymphovascular invasion, visceral pleural invasion, tumor necrosis and bronchial resection margin (BRM) < 2 cm were significant prognostic factors for tumor recurrence. However, tumor size ≥ 4 cm, visceral pleural invasion, tumor necrosis and BRM < 2 cm remained the significant prognostic factors with multivariate analysis (Table). Sensitizing EGFR mutation was not a significant prognostic factor in this cohort by both univariate and multivariate analyses.Table: 1451P

Multivariate analysis

CovariateHR95% CIP-value
Tumor size ≥ 4 cm1.961.1 - 3.60.03
Visceral Pleural invasion2.381.3 - 4.30.004
< 2 cm of bronchial resection margin2.481.4 - 4.30.002
Tumor necrosis3.121.7 - 5.6< 0.001
EGFR mutation1.230.6 - 2.70.57


Among Thai, East Asian, early stage lung cancer, sensitizing EGFR mutation has similar outcomes to those without EGFR mutation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Ratchadapisek Sompoch Endowment Fund.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.